 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Medytox has applied for approval of botulinum toxin formulation items with the aim of entering the US market in 2025. In 2013, we exported our technology to Allergan, an American pharmaceutical company It is the first challenge in 10 years since it was returned.
Medytox announced on the 28th that it has submitted a permission application (BLA) to the U.S. Food and Drug Administration (FDA) for the non-animal liquid botulinum toxin drug "MT10109L," which is an indication for scoliosis, severe brow wrinkles and eye wrinkles.
Medytox is preparing factory due diligence and marketing management strategies with the aim of launching the local market in 2025.
Meanwhile, Medytox announced on the 26th that Allergan filed a claim against the 'transfer of data in violation of the license contract and compensation for damages' filed against Allergan in September last year. As Allergan was acquired by AbbVie in 2019, development rights were transferred to AbbVie, and in 2021, AbbVie returned the right to develop and commercialize the material to Medytox. In response, Medytox filed a lawsuit with the International Chamber of Commerce (ICC) seeking about 35.1 billion won against Allergan, including costs and damages, and Allergan filed a counterclaim on the 21st.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
